Cargando…

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells

Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive therapeutic target. So far, applications of FLT3 small molecule inhibitors have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roolf, Catrin, Dybowski, Nikolaj, Sekora, Anett, Mueller, Stefan, Knuebel, Gudrun, Tebbe, Andreas, Murua Escobar, Hugo, Godl, Klaus, Junghanss, Christian, Schaab, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Biochemistry and Molecular Biology 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500767/ https://www.ncbi.nlm.nih.gov/pubmed/28450419 http://dx.doi.org/10.1074/mcp.M117.067462

Ejemplares similares

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Kinetics of Langerhans cell chimerism in the skin of dogs following 2 Gy TBI allogeneic hematopoietic stem cell transplantation
por: Peters, Sabrina, et al.
Publicado: (2016)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

Identifying differentially regulated subnetworks from phosphoproteomic data
por: Klammer, Martin, et al.
Publicado: (2010)

Combined BCL-2 and PI3K/AKT Pathway Inhibition in KMT2A-Rearranged Acute B-Lymphoblastic Leukemia Cells
por: Holz, Clemens, et al.
Publicado: (2023)

The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models
por: Richter, Anna, et al.
Publicado: (2022)

Ultradeep targeted sequencing reveals low allele frequencies of somatic JAK2 and MPL variants in patients with abdominal vein thromboses: results of an ongoing prospective prevalence study in Mecklenburg-West Pomerania
por: Grunwald, Luise, et al.
Publicado: (2020)

Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2019)

Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements
por: Roolf, C., et al.
Publicado: (2018)

Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells
por: Roolf, Catrin, et al.
Publicado: (2019)

Polymorphisms of the murine mitochondrial ND4, CYTB and COX3 genes impact hematopoiesis during aging
por: Kretzschmar, Christin, et al.
Publicado: (2016)

Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
por: Richter, Anna, et al.
Publicado: (2022)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
por: Schaab, C, et al.
Publicado: (2014)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
por: Cucchi, David G. J., et al.
Publicado: (2021)

Characterization of the novel indolylmaleimides' PDA-66 and PDA-377 effect on canine lymphoma cells
por: Liu, Wen, et al.
Publicado: (2016)

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells
por: Kretzschmar, Christin, et al.
Publicado: (2014)

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021)

Spirooxindol‐1,3‐oxazine Alkaloids: Highly Potent and Selective Antitumor Agents Evolved from Iterative Structure Optimization
por: Eichhorst, Annika, et al.
Publicado: (2022)

Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML
por: Schmidt, Franziska, et al.
Publicado: (2022)

Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse
por: Gladbach, Yvonne Saara, et al.
Publicado: (2022)

Establishment and characterization of stable red, far-red (fR) and near infra-red (NIR) transfected canine prostate cancer cell lines
por: Liu, Wen, et al.
Publicado: (2020)

Identification of Significant Features by the Global Mean Rank Test
por: Klammer, Martin, et al.
Publicado: (2014)

Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib
por: Klammer, Martin, et al.
Publicado: (2015)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach
por: Sender, Sina, et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells
por: Kong, Weibo, et al.
Publicado: (2021)

Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

PDA Indolylmaleimides Induce Anti-Tumor Effects in Prostate Carcinoma Cell Lines Through Mitotic Death
por: Schille, Jan Torben, et al.
Publicado: (2021)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
por: Diral, Elisa, et al.
Publicado: (2023)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
por: Ma, Yixuan, et al.
Publicado: (2022)

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines
por: Sklarz, L.-M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_18v1j0a83ffjqat3bpguov4na2